Study of the MIB-1 Labeling Index as a Predictor of Tumor Progression in Pilocytic Astrocytomas in Children and Adolescents

Abstract

Children with PAs with an MIB-1 LI of more than 2.0 have a shortened PFS. PAs that are completely resected and are located in the cerebellum have a prolonged PFS. This initial study suggests that the MIB-1 LI identifies a more aggressive subset of PAs. Further work should focus on elucidating features of pilocytic astocytomas that will identify prospectively children at risk for progression.

Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas--an assessment of 3 new variables in predicting clinical outcome

“…24 Our method of quantification is the one most widely used and is the same as was performed in our previous study. 2 As the same counting methodology was used for the analysis of all 3 of the proliferative markers in this study, this provides a useful comparison of their benefits.…”

“…Fifty-five of these cases were included in the previously reported series of 141 consecutively diagnosed cases of PAs from our institution. 2 …”

“…1 A 38.7% progression rate has been reported in a series of 141 cases of PAs from our institution. 2 The only wellestablished prognostic variables that identify children at higher risk for recurrence are the closely interrelated factors of tumor location and the degree of surgical resection. An elevated MIB-1 labeling index (MIB-LI), an immunohistochemical estimation of the proportion of cells in the growth phase of the cell cycle, has also been shown to be associated with an increased likelihood of tumor progression in PAs.…”

“…An elevated MIB-1 labeling index (MIB-LI), an immunohistochemical estimation of the proportion of cells in the growth phase of the cell cycle, has also been shown to be associated with an increased likelihood of tumor progression in PAs. 2 The use of immunohistochemistry-based biologic markers to predict cancer prognosis and response to therapy is becoming widespread in diagnostic pathology today. MIB-1 immunostaining has become an invaluable tool in accurately categorizing gliomas and other brain tumors.…”

Ki-67 is a Valuable Prognostic Factor in Gliomas: Evidence from a Systematic Review and Meta-analysis

“…Of the candidate studies, 13 articles failed to completely describe the available survival data. Finally, 51 published studies in total were included in the analysis after eliminating articles unsatisfying the selection criteria and duplicates (Jaros et al, 1992;Torp et al, 1992;Montine et al, 1994;Ellison et al, 1995;Heegaard et al, 1995;Kros et al, 1996;Coons et al, 1997;Pollack et al, 1997;Dehghani et al, 1998;McKeever et al, 1998;Ritter et al, 1998;Figarella-Branger et al, 2000;Rodriguez-Pereira et al, 2000;Ho et al, 2001;ReaveyCantwell et al, 2001;Zhong et al, 2001;Bredel et al, 2002;Pollack et al, 2002;Bowers, 2003;Chiang et al, 2003;Neder et al, 2003;Wessels et al, 2003;Zamecnik et al, 2003;Preusser et al, 2005;Uematsu et al, 2005;Kleinschmidt-DeMasters et al, 2006;Donato et al, 2007;Kanamori et al, 2008;Kuo et al, 2009;Laks et al, 2009;Li et al, 2009;Armstrong et al, 2010;Nabika et al, 2010;Watanabe et al, 2010;Yoshida et al, 2010;Habberstad et al, 2011;Margraf et al, 2011;Qiang et al, 2011;Shen et al, 2011;Zawrocki et al, 2011;…”